Martin Himly (ORCID: 0000-0001-5416-085X) studied Chemistry/Biotechnology at the University of Graz (Austria) and received his PhD in 2001. He performed research abroad at The Scripps Research Institute, La Jolla, CA, USA in the field of oncology and virology. He has a strong background in recombinant allergen diagnostics/vaccines, standardization of allergen therapeutics (Biological Standardization Program BSP090, EDQM, Strasbourg, FR), characterization of protein pharmaceutics, biochemistry, and immunology. He joined the Bio-Nano Group of Albert Duschl in 2012 and has a vivid interest in applying realistic advanced cellular co-culture models investigating immune mechanisms of nanomaterials, bio-nano conjugates, and nanomedical candidates. He has been involved in a number of FP7 and H2020 projects in nanosafety (NanoTOES, NanoValid, NanoEIS, PANDORA, HUMUNITY, EC4SafeNano, NanoCommons, NanoRigo) and coordinated the educational Sparkling Science project “Nan-O-Style” www.uni-salzburg.at/nan-o-style). Martin Himly holds an Associate Professor position in Biochemistry and Immunology at the Department of Biosciences of the Paris Lodron University of Salzburg (PLUS) and is member of the Allergy-Cancer-BioNano Research Center (ACBN) and the Doctoral School DSP Biomolecules of PLUS.
Cathrin Cailliau is a Science Communication specialist at Yordas Germany. She has worked as both a researcher and communicator, first at the University of Applied Sciences in Munich and then at the Nuremberg Institute of Technology in Germany. She holds an M.Sc. in Global Change Ecology from the University of Bayreuth. Currently, she is involved in the communication, dissemination and training of the Horizon 2020 EU research projects CHARISMA, SbD4Nano, SUNSHINE and the Horizon Europe project IMPROVE. She is an active member of the NSC Dissemination Group and co-chair of the NSC work group on Communication, Training and Education (deputising for Stella Stoycheva).